319 related articles for article (PubMed ID: 35454923)
1. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
Machairas N; Tsilimigras DI; Pawlik TM
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454923
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
Scheiner B; Roessler D; Phen S; Lim M; Pomej K; Pressiani T; Cammarota A; Fründt TW; von Felden J; Schulze K; Himmelsbach V; Finkelmeier F; Deibel A; Siebenhüner AR; Shmanko K; Radu P; Schwacha-Eipper B; Ebert MP; Teufel A; Djanani A; Hucke F; Balcar L; Philipp AB; Hsiehchen D; Venerito M; Sinner F; Trauner M; D'Alessio A; Fulgenzi CAM; Pinato DJ; Peck-Radosavljevic M; Dufour JF; Weinmann A; Kremer AE; Singal AG; De Toni EN; Rimassa L; Pinter M
JHEP Rep; 2023 Jan; 5(1):100620. PubMed ID: 36578451
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC; Ruff SM; Pawlik TM
Front Immunol; 2024; 15():1355812. PubMed ID: 38495884
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
Ouyang T; Kan X; Zheng C
Front Oncol; 2022; 12():898964. PubMed ID: 35785169
[TBL] [Abstract][Full Text] [Related]
5. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
6. Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?
Himmelsbach V; Koch C; Trojan J; Finkelmeier F
J Hepatocell Carcinoma; 2024; 11():363-372. PubMed ID: 38405324
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
[TBL] [Abstract][Full Text] [Related]
8. Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials.
Yu J; Li M; Ren B; Cheng L; Wang X; Ma Z; Yong WP; Chen X; Wang L; Goh BC
Front Pharmacol; 2023; 14():1261575. PubMed ID: 37719852
[TBL] [Abstract][Full Text] [Related]
9. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y
Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.
Katariya NN; Lizaola-Mayo BC; Chascsa DM; Giorgakis E; Aqel BA; Moss AA; Uson Junior PLS; Borad MJ; Mathur AK
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565184
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
12. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.
Chen L; Zhang R; Lin Z; Tan Q; Huang Z; Liang B
Front Immunol; 2023; 14():1100079. PubMed ID: 36742293
[TBL] [Abstract][Full Text] [Related]
13. Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma.
Chan LL; Chan SL
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326677
[TBL] [Abstract][Full Text] [Related]
14. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Bangaru S; Marrero JA; Singal AG
Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
[TBL] [Abstract][Full Text] [Related]
15. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
16. Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma.
Whitham Z; Hsiehchen D
Surg Oncol Clin N Am; 2024 Jan; 33(1):87-97. PubMed ID: 37945147
[TBL] [Abstract][Full Text] [Related]
17. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
Yin X; Wu T; Lan Y; Yang W
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
[TBL] [Abstract][Full Text] [Related]
18. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
Chan LL; Chan SL
Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
[TBL] [Abstract][Full Text] [Related]
19. Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma.
Chu PY; Chan SH
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771459
[TBL] [Abstract][Full Text] [Related]
20. Advances in pharmacotherapeutics for hepatocellular carcinoma.
Cerrito L; Santopaolo F; Monti F; Pompili M; Gasbarrini A; Ponziani FR
Expert Opin Pharmacother; 2021 Jul; 22(10):1343-1354. PubMed ID: 33637024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]